JPWO2022164935A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022164935A5 JPWO2022164935A5 JP2023545274A JP2023545274A JPWO2022164935A5 JP WO2022164935 A5 JPWO2022164935 A5 JP WO2022164935A5 JP 2023545274 A JP2023545274 A JP 2023545274A JP 2023545274 A JP2023545274 A JP 2023545274A JP WO2022164935 A5 JPWO2022164935 A5 JP WO2022164935A5
- Authority
- JP
- Japan
- Prior art keywords
- particle
- polynucleotide sequence
- sequence encoding
- surface receptor
- cell surface
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163142347P | 2021-01-27 | 2021-01-27 | |
| US63/142,347 | 2021-01-27 | ||
| US202163185765P | 2021-05-07 | 2021-05-07 | |
| US63/185,765 | 2021-05-07 | ||
| PCT/US2022/013947 WO2022164935A1 (en) | 2021-01-27 | 2022-01-26 | Lentivirus for generating cells expressing anti-cd19 chimeric antigen receptor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024505887A JP2024505887A (ja) | 2024-02-08 |
| JPWO2022164935A5 true JPWO2022164935A5 (https=) | 2025-01-22 |
| JP2024505887A5 JP2024505887A5 (https=) | 2025-01-22 |
Family
ID=80624056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023545274A Pending JP2024505887A (ja) | 2021-01-27 | 2022-01-26 | 抗ｃｄ１９キメラ抗原受容体を発現する細胞を生成するためのレンチウイルス |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240141375A1 (https=) |
| EP (1) | EP4284821A1 (https=) |
| JP (1) | JP2024505887A (https=) |
| KR (1) | KR20230143150A (https=) |
| AU (1) | AU2022212952A1 (https=) |
| BR (1) | BR112023014980A2 (https=) |
| CA (1) | CA3206009A1 (https=) |
| IL (1) | IL304506A (https=) |
| MX (1) | MX2023008831A (https=) |
| WO (1) | WO2022164935A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2934532B1 (en) | 2012-12-20 | 2019-10-23 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| JP7178355B2 (ja) | 2017-02-28 | 2022-11-25 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞療法のための組成物および方法 |
| JP7549303B2 (ja) | 2018-01-22 | 2024-09-11 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞の使用方法 |
| CN112105382A (zh) | 2018-02-23 | 2020-12-18 | 恩多塞特公司 | 用于car t细胞疗法的顺序方法 |
| CN112262214A (zh) | 2018-04-12 | 2021-01-22 | 优莫佳生物制药股份有限公司 | 病毒载体及包装细胞系 |
| US12419913B2 (en) | 2019-02-08 | 2025-09-23 | Dna Twopointo, Inc. | Modification of CAR-T cells |
| US20240122978A1 (en) * | 2019-10-16 | 2024-04-18 | Umoja Biopharma, Inc. | Retroviral vector for univeral receptor therapy |
| AU2021287998B2 (en) | 2020-06-11 | 2026-03-12 | Benaroya Research Institute At Virginia Mason | Methods and compositions for preventing type 1 diabetes |
| US12565529B2 (en) | 2021-05-24 | 2026-03-03 | Provention Bio, Inc. | Methods for treating type 1 diabetes |
| WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2024081820A1 (en) | 2022-10-13 | 2024-04-18 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
| JP2026500897A (ja) * | 2022-11-04 | 2026-01-09 | ウモジャ バイオファーマ インコーポレイテッド | 融合分子を呈示するレンチウイルス粒子およびその使用 |
| TW202434621A (zh) * | 2022-11-04 | 2024-09-01 | 美商優莫佳生物製藥有限公司 | 多核苷酸構築體及相關病毒載體及方法 |
| WO2024216227A1 (en) * | 2023-04-12 | 2024-10-17 | Vyriad | Cd3-redirected vectors, components thereof, and uses of the vectors and components thereof |
| EP4694916A1 (en) | 2023-04-14 | 2026-02-18 | SOTIO Biotech Inc. | Engineered immune cells for treating cancer in combination with il-2/il-15 receptor ?? agonists |
| WO2024215987A1 (en) | 2023-04-14 | 2024-10-17 | Sotio Biotech Inc. | IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES |
| WO2024220598A2 (en) | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Lentiviral vectors with two or more genomes |
| KR20260005358A (ko) | 2023-04-27 | 2026-01-09 | 밀테니 비오텍 비.브이. & 씨오. 케이지 | 항-cd3 디스플레이를 갖는 슈도타이핑된 레트로바이러스 벡터 입자 |
| WO2024238153A1 (en) * | 2023-05-15 | 2024-11-21 | Umoja Biopharma, Inc. | Lentiviral delivery of anti-cd20 chimeric antigen receptors |
| KR20260016952A (ko) | 2023-05-23 | 2026-02-04 | 사나 바이오테크놀로지, 인크. | 탠덤 퓨소젠 및 관련 지질 입자 |
| WO2025078492A1 (en) | 2023-10-13 | 2025-04-17 | Miltenyi Biotec B.V. & Co. KG | Cd3-targeted nipah-pseudotyped lentiviral vector particles |
| WO2025102013A1 (en) * | 2023-11-10 | 2025-05-15 | Vyriad | Rhabdovirus g proteins having one or more cysteine-rich regions and uses thereof |
| WO2025176853A1 (en) | 2024-02-22 | 2025-08-28 | Miltenyi Biotec B.V. & Co. KG | Cd4- or cd8-targeted retroviral vector particles for generation of cells expressing a bispecific chimeric antigen receptor |
| WO2025212519A1 (en) | 2024-04-01 | 2025-10-09 | Moonlight Bio, Inc. | Dll3 binding proteins and uses thereof |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
| US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| DE69434860T2 (de) | 1993-02-22 | 2007-03-15 | The Rockefeller University | Herstellung von helfer-freien retroviren mit hohem titer mittels transienter transfektion |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| FR2712812B1 (fr) | 1993-11-23 | 1996-02-09 | Centre Nat Rech Scient | Composition pour la production de produits thérapeutiques in vivo. |
| IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5948893A (en) | 1996-01-17 | 1999-09-07 | The United States Of America As Represented By The Secretary Of The Navy | Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| NZ532635A (en) | 2001-11-13 | 2007-05-31 | Univ Pennsylvania | A method of identifying unknown adeno-associated virus (AAV) sequences and a kit for the method |
| US9434928B2 (en) | 2011-11-23 | 2016-09-06 | Nationwide Children's Hospital, Inc. | Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides |
| WO2013148327A1 (en) | 2012-03-26 | 2013-10-03 | The Regents Of The University Of California | Nipah virus envelope psuedotyped lentiviruses and methods of their use |
| EP2895203A4 (en) * | 2012-06-15 | 2016-09-28 | Imaginab Inc | ANTIGENBINDING CONSTRUCTS FOR CD3 |
| WO2015017214A1 (en) * | 2013-07-29 | 2015-02-05 | Bluebird Bio, Inc. | Multipartite signaling proteins and uses thereof |
| US10287354B2 (en) * | 2013-12-20 | 2019-05-14 | Novartis Ag | Regulatable chimeric antigen receptor |
| GB201503500D0 (en) | 2015-03-02 | 2015-04-15 | Ucl Business Plc | Cell |
| IL261713B2 (en) * | 2016-03-19 | 2023-09-01 | F1 Oncology Inc | Methods and preparations for the transfer of lymphocytes and their regulated expansion |
| JP7206214B2 (ja) | 2016-12-13 | 2023-01-17 | シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） | インビトロ及びインビボで操作された細胞において発現された化学誘導シグナル伝達複合体の外因性薬物活性化の方法 |
| CN111479921B (zh) * | 2017-09-18 | 2024-08-02 | 埃克苏马生物技术公司 | 用于以基因方式修饰且扩增淋巴细胞以及调节其活性的方法及组合物 |
| AU2018337142B2 (en) | 2017-09-22 | 2025-07-03 | Wuxi Biologics Ireland Limited. | Novel bispecific CD3/CD19 polypeptide complexes |
| ES2991089T3 (es) | 2017-09-22 | 2024-12-02 | Centre Nat Rech Scient | Glicoproteína mutada del virus de la estomatitis vesicular |
| MA51158A (fr) * | 2017-12-14 | 2020-10-21 | Bluebird Bio Inc | Récepteurs daric nkg2d |
| CN112262214A (zh) | 2018-04-12 | 2021-01-22 | 优莫佳生物制药股份有限公司 | 病毒载体及包装细胞系 |
| CA3091490A1 (en) * | 2018-04-27 | 2019-10-31 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Rapamycin resistant cells |
| WO2020106992A1 (en) | 2018-11-21 | 2020-05-28 | Umoja Biopharma, Inc. | Multicistronic vector for surface engineering lentiviral particles |
-
2022
- 2022-01-26 MX MX2023008831A patent/MX2023008831A/es unknown
- 2022-01-26 EP EP22706707.1A patent/EP4284821A1/en active Pending
- 2022-01-26 AU AU2022212952A patent/AU2022212952A1/en active Pending
- 2022-01-26 US US18/262,859 patent/US20240141375A1/en active Pending
- 2022-01-26 CA CA3206009A patent/CA3206009A1/en active Pending
- 2022-01-26 WO PCT/US2022/013947 patent/WO2022164935A1/en not_active Ceased
- 2022-01-26 KR KR1020237028818A patent/KR20230143150A/ko active Pending
- 2022-01-26 BR BR112023014980A patent/BR112023014980A2/pt unknown
- 2022-01-26 JP JP2023545274A patent/JP2024505887A/ja active Pending
-
2023
- 2023-07-17 IL IL304506A patent/IL304506A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2022164935A5 (https=) | ||
| Marofi et al. | CAR‐NK cell in cancer immunotherapy; A promising frontier | |
| Frank et al. | Combining T-cell–specific activation and in vivo gene delivery through CD3-targeted lentiviral vectors | |
| JP2024074937A (ja) | 細胞免疫療法のための方法および組成物 | |
| Li et al. | Increasing the safety and efficacy of chimeric antigen receptor T cell therapy | |
| Lanitis et al. | Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo | |
| Gargett et al. | The inducible caspase-9 suicide gene system as a “safety switch” to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells | |
| Li et al. | CAR-T cells for Colorectal Cancer: Target-selection and strategies for improved activity and safety | |
| JP2022184852A5 (https=) | ||
| Nolan et al. | Bypassing immunization: optimized design of “designer T cells” against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA | |
| Spear et al. | Strategies to genetically engineer T cells for cancer immunotherapy | |
| JP2021525524A5 (https=) | ||
| CN110872577A (zh) | 修饰的免疫细胞及其应用 | |
| CN109280086B (zh) | 一种肿瘤微环境特异性活化的缺氧诱导型嵌合抗原受体 | |
| Murad et al. | Advances in the use of natural receptor-or ligand-based chimeric antigen receptors (CARs) in haematologic malignancies | |
| Han et al. | Recent clinical trials utilizing chimeric antigen receptor T cells therapies against solid tumors | |
| WO2019223226A1 (zh) | 改良型抗cd19 car-t细胞 | |
| Rosenzweig et al. | Preclinical data support leveraging CS1 chimeric antigen receptor T-cell therapy for systemic light chain amyloidosis | |
| Haist et al. | Engineering a single-chain variable fragment of cetuximab for CAR T-cell therapy against head and neck squamous cell carcinomas | |
| AU2018349093A1 (en) | T cell-antigen coupler with Y182T mutation and methods and uses thereof | |
| Ren et al. | Modification of cytokine-induced killer cells with chimeric antigen receptors (CARs) enhances antitumor immunity to epidermal growth factor receptor (EGFR)-positive malignancies | |
| Guo et al. | Humanized CD30-targeted chimeric antigen receptor t cells exhibit potent preclinical activity against Hodgkin’s lymphoma cells | |
| JPWO2020051493A5 (https=) | ||
| WO2024113714A1 (zh) | 敲低nkg2a基因的car-免疫细胞及其用途 | |
| WO2020176897A1 (en) | Chimeric antigen receptors and uses thereof |